OncoSec Medical (ONCS) Gets a Buy Rating from H.C. Wainwright

By Ryan Adsit

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS), with a price target of $4. The company’s shares closed on Friday at $1.61.

Selvaraju wrote:

“Our price target is derived from a market value of $260M for OncoSec, which includes a discounted cash flow-based asset value for ImmunoPulse IL-12, with 15% discount rate, 0% terminal growth rate and 30% probability of success.”

According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.2% and a 31.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for OncoSec Medical with a $4.50 average price target, a 179.5% upside from current levels. In a report issued on October 15, Maxim Group also maintained a Buy rating on the stock with a $5 price target.


See today’s analyst top recommended stocks >>

Based on OncoSec Medical’s latest earnings release for the quarter ending April 30, the company reported a quarterly GAAP net loss of $10.06 million. In comparison, last year the company had a GAAP net loss of $5.9 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications.